title: HYOU1/Orp150 expression in breast cancer.
abstract: BACKGROUND
  Heat shock protein HYOU1, alternatively known as Orp150, plays an important role in hypoxia/ischemia and angiogenesis. Preliminary studies demonstrated increased HYOU1/Orp150 expression in prostate, bladder and invasive breast cancer. This study further evaluates HYOU1/Orp150 expression in different stages of breast cancer such as benign, pre-malignant and malignant lesions, and correlates it with clinical and pathological data.
  
  
  METHODS
  Sixty-six paraffin-embedded breast tissue sections were stained by immunohistochemistry using HYOU1/Orp150 antibody. Antibody staining was reviewed and scored 0 (lowest) to 3+ (highest). Clinico-pathological data was compared with HYOU1/Orp150 staining using ANOVA or Student's t-Test as appropriate with significance determined by P<0.05.
  
  
  RESULTS
  There was a small but significant increase (P<0.01) in HYOU1/Orp150 expression as the tumor transformed from benign (mean 1.52+/-0.12) to ductal carcinoma in situ (mean 2.05+/-0.14) and invasive carcinoma (mean 2.1+/-0.17). HYOU1/Orp150 was partially lost in the benign tissue adjacent to purely invasive cancer (0.88+/-0.22) and it was less (P=0.046) than what was found in benign only lesions (1.52+/-0.12) or in benign components adjacent to DCIS (1.47+/-0.16). Overexpression of HYOU1/Orp150 was associated with tumor lymph node involvement, presence of lymphovascular invasion, and absence of estrogen receptor expression (P<0.01). A trend was observed between HYOU1/Orp150 and nuclear p53 overexpression (P<0.04), but no correlation was detected with age, TNM stage, PR status, HER2/neu or Ki67.
  
  
  CONCLUSIONS
  HYOU1/Orp150 is overexpressed in some invasive breast cancers and its overexpression appears to be associated with indicators of poor prognosis. Its association with factors such as lymphovascular invasion and regional nodal involvement suggests a possible role for HYOU1/Orp150 in metastasis.
authors.affiliation: Department of Surgery, Surgical Oncology, Walter Reed Army Medical Center, Washington, DC, USA. alexander.stojadinovic@na.amedd.army.mil
authors.forename: Alexander
authors.initials: A
authors.lastname: Stojadinovic
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Hooke
authors.forename: Craig D
authors.initials: CD
authors.lastname: Shriver
authors.forename: Aviram
authors.initials: A
authors.lastname: Nissan
authors.forename: Albert J
authors.initials: AJ
authors.lastname: Kovatich
authors.forename: Tzu-Cheg
authors.initials: TC
authors.lastname: Kao
authors.forename: Sathibalan
authors.initials: S
authors.lastname: Ponniah
authors.forename: George E
authors.initials: GE
authors.lastname: Peoples
authors.forename: Maria
authors.initials: M
authors.lastname: Moroni
mesh_terms: D001941:Breast Diseases / Q000378:metabolism; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000378:metabolism; D005260:Female; D018840:HSP70 Heat-Shock Proteins; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011379:Prognosis; D011506:Proteins / Q000378:metabolism*; D012189:Retrospective Studies
chemical_list: D018840:HSP70 Heat-Shock Proteins; D011506:Proteins; C050087:oxygen-regulated proteins